NCT06253429View on ClinicalTrials.gov

Alpha-lipoic Acid in Diabetic Nephropathy

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

February 1, 2024

Conditions
Type 1 Diabetes
Interventions
DRUG

Thioctic Acid 333 MG Oral Capsule

Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes

DRUG

Captopril 25Mg Tab

Oral angiotensin-converting enzyme inhibitors

Trial Locations (1)

11765

RECRUITING

Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06253429 - Alpha-lipoic Acid in Diabetic Nephropathy | Biotech Hunter | Biotech Hunter